Hazard Information | Back Directory | [Uses]
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer[1][2]. | [References]
[1] Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26(14):3557-3564. DOI:10.1158/1078-0432.CCR-20-0426 [2] Julian A Marin-Acevedo, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12;11(1):8. DOI:10.1186/s13045-017-0552-6 |
|
Company Name: |
Biolab Reagents
|
Tel: |
027-65279366 18108604356 |
Website: |
www.biolabreagent.com/ |
|